Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.

Joshi H, Bhanot G, Børresen-Dale AL, Kristensen V.

Br J Cancer. 2012 Nov 6;107(10):1722-8. doi: 10.1038/bjc.2012.461. Epub 2012 Oct 18.

2.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA.

Clin Cancer Res. 2003 Apr;9(4):1253-8.

3.

Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.

Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard MV, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ.

J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.

PMID:
24687952
4.

Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.

Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Børresen-Dale AL, Tost J, Kristensen V.

Mol Oncol. 2011 Feb;5(1):61-76. doi: 10.1016/j.molonc.2010.11.004. Epub 2010 Nov 25.

5.

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G.

Breast Cancer Res. 2012 Nov 12;14(6):R145. doi: 10.1186/bcr3354.

6.

Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.

Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA, Donehower LA.

J Pathol. 2014 Apr;232(5):522-33. doi: 10.1002/path.4321. Epub 2014 Jan 29.

7.

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassøe AM, Thorsen T, Berntsen H, Børresen-Dale AL, Akslen LA, Lønning PE.

Eur J Cancer. 2003 Mar;39(4):438-46.

PMID:
12751373
8.

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.

Breast Cancer Res. 2007;9(3):R30.

9.

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.

Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L.

Mol Oncol. 2014 May;8(3):508-19. doi: 10.1016/j.molonc.2013.12.018. Epub 2014 Jan 5.

10.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.

PMID:
24074787
11.

p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.

Liang Y, Wu J, Stancel GM, Hyder SM.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):173-82. Epub 2005 Jan 28.

PMID:
15860260
12.

Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.

van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerød A, Van't Veer LJ, Schmidt MK.

Breast Cancer Res Treat. 2011 Nov;130(2):599-608. doi: 10.1007/s10549-011-1615-y. Epub 2011 Jun 11.

PMID:
21667122
13.

Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines.

Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M.

Breast Cancer Res Treat. 2011 Jan;125(1):35-42. doi: 10.1007/s10549-010-0819-x. Epub 2010 Mar 11.

PMID:
20221692
14.

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.

Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J.

Acta Oncol. 2000;39(3):327-33.

PMID:
10987229
15.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
16.

Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.

Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N.

Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.

PMID:
26171916
17.

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.

King SI, Purdie CA, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Meek DW.

Breast Cancer Res. 2012 Mar 8;14(2):R40.

18.

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M.

Breast Cancer Res. 2012 May 2;14(3):R70.

19.

Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.

Uji K, Naoi Y, Kagara N, Shimoda M, Shimomura A, Maruyama N, Shimazu K, Kim SJ, Noguchi S.

Cancer Lett. 2014 Jan 1;342(1):19-26. doi: 10.1016/j.canlet.2013.08.028. Epub 2013 Aug 21.

PMID:
23973262
20.

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.

Dobes P, Podhorec J, Coufal O, Jureckova A, Petrakova K, Vojtesek B, Hrstka R.

Oncol Rep. 2014 Oct;32(4):1695-702. doi: 10.3892/or.2014.3346. Epub 2014 Jul 21.

PMID:
25051299

Supplemental Content

Support Center